The Spinoff Tease – Glaxo Scraps Plans For ViiV IPO
We have written about British pharma giant GlaxoSmithKline (GSK) a number of times over the past few years, but so far, none of the rumored spinoffs have ever come to fruition. It seems that will remain the case, as CEO Andrew Witty announced that the company would not be pursuing a spinoff of its HIV-centric Viiv. GSK owns over 80%… Read More »